Close Menu

DeciBio

Data amassed by analytics firm Diaceutics suggests fewer patients are coming into healthcare facilities and missing the chance for diagnosis, molecular testing, and treatment.

The market for next-generation sequencing-based molecular diagnostic tests is poised to grow more than tenfold between 2012 and 2015, driven by non-invasive prenatal and oncology tests, most of them targeted, according to a recent report from research firm DeciBio.

Next-generation sequencing is helping to drive the emerging market in single-cell genomics, according to a report by Culver City, Calif.-based market research firm DeciBio.

The next-generation sequencing market is poised to grow 20 percent per year from around $1.2 billion currently to $2.1 billion by 2015, driven in large part by desktop sequencers, according to a recent report by Los Angeles-based market research firm DeciBio.

Fluidigm's product revenues are expected to grow 27 percent annually over the next four years, buoyed by the company's participation in three rapidly growing niche markets — sample preparation for next-gen sequencing, single-cell genomics, and digital PCR — according to a market

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.

Science reports that a new White House Office of Management and Budget memo rescinds previous ones that helped research institutions deal with pandemic-related closures.